指南与共识肾小球疾病

KDIGO 2025 IgA肾病和IgA血管炎管理临床实践指南执行摘要

Executive summary of the KDIGO 2025 Clinical Practice Guideline for the Management of Immunoglobulin A Nephropathy (IgAN) and Immunoglobulin A Vasculitis (IgAV).
指南 / 共识 · Kidney Int · 2025-01-01

KDIGO 2025年IgA肾病(IgAN)和IgA血管炎(IgAV)管理指南是对2021年版指南的重大更新。新指南鼓励更宽松的肾活检政策,建议更严格的蛋白尿控制目标(<0.5 g/d,理想<0.3 g/d)并维持eGFR稳定。核心新概念是初始治疗应同时针对减少致病性IgA产生及管理IgAN所致肾单位丢失的后果。

要点

  • 新指南鼓励更宽松的肾活检政策,并建议更严格的蛋白尿控制目标:<0.5 g/d,理想<0.3 g/d,且eGFR稳定。
  • 核心新概念:初始治疗应同时包括减少致病性IgA产生和IgA/IgG免疫复合物形成的疗法,以及管理IgAN所致肾单位丢失后果的疗法。
  • 减少致病性IgA产生的疗法目前限于靶向释放布地奈德(Nefecon)或减量全身性糖皮质激素,中国患者可用吗替麦考酚酯。

核心结论

  • KDIGO 2025 IgAN指南鼓励更宽松的肾活检政策,建议更严格的蛋白尿控制目标(<0.5 g/d,理想<0.3 g/d)并维持eGFR稳定。
  • 核心新概念是初始治疗应同时针对减少致病性IgA产生及管理IgAN所致肾单位丢失的后果。

研究设计与样本

  • 指南制定机构为KDIGO(改善全球肾脏病预后组织),方法为基于新进展对2021年肾小球疾病管理指南中的IgAN和IgAV管理部分进行重大更新。

主要发现

  • 与上一版相比,2025版指南鼓励更宽松的肾活检政策,并建议更严格的蛋白尿控制目标:<0.5 g/d,理想<0.3 g/d,且eGFR稳定。

关键数值与推荐

  • 建议更严格的蛋白尿控制目标:<0.5 g/d,理想<0.3 g/d,并维持eGFR稳定。
  • 减少致病性IgA产生的疗法目前限于靶向释放布地奈德(Nefecon)或减量全身性糖皮质激素,中国患者可用吗替麦考酚酯。
  • 管理IgAN所致肾单位丢失后果的疗法包括健康生活方式教育、RAS阻断剂、SGLT2抑制剂和/或双重内皮素血管紧张素受体拮抗剂。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 针对肾病综合征、急性肾损伤、急进性肾小球肾炎、妊娠期IgAN以及儿童IgAN或IgAV等特殊 situations 缺乏大型临床试验,因此相关管理变化不大。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

The Immunoglobulin A nephropathy (IgAN) and Immunoglobulin A vasculitis (IgAV) management guideline was last updated and published as part of the Kidney Disease: Improving Global Outcomes (KDIGO) 2021 Clinical Practice Guideline for the Management of Glomerular Diseases. Based on new developments in IgAN assessment and therapy, a major update of the guideline was necessary in 2024. Compared with the last version, the KDIGO 2025 IgAN guideline now encourages a more liberal kidney biopsy policy and suggests aiming for stricter proteinuria control, with a goal of <0.5 g/d, ideally <0.3 g/d, and a stable estimated glomerular filtration rate. A major new concept in the 2025 guideline is to initiate treatment with (i) therapies that prevent or reduce pathogenic IgA production and IgA/IgA and IgA/IgG immune complex formation along with (ii) therapies to manage the consequences of existing IgAN-induced nephron loss. Approaches to achieve the first aim are currently limited to targeted-release budesonide (Nefecon) or reduced-dose systemic corticosteroid therapy and, in Chinese patients, mycophenolate mofetil. Approaches to the more generic second aim include healthy lifestyle education, renin-angiotensin system blockers, sodium-glucose cotransporter-2 inhibitors, and/or dual endothelin angiotensin receptor blockers. Little has changed for special situations of IgA-dominant immune complex glomerular diseases such as nephrotic syndrome, acute kidney injury, rapidly progressive glomerulonephritis, and pregnancy in IgAN, or children with IgAN or IgAV, given the lack of major clinical trials in these patient populations. Here, we provide an executive summary of the most important changes in the KDIGO 2025 IgAN and IgAV guideline as a quick reference.

来源:Kidney Int,查看原文。版权归原作者所有。

引用

  1. Floege J, Barratt J, Cook HT, et al. Executive summary of the KDIGO 2025 Clinical Practice Guideline for the Management of Immunoglobulin A Nephropathy (IgAN) and Immunoglobulin A Vasculitis (IgAV). Kidney Int. 2025. PMID: 40975525. doi:10.1016/j.kint.2025.04.003

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。